If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $54.15, a high estimate of ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

(Reuters) - Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.

Ionis licensed this drug to Biogen, which is responsible for ... which was approved by the FDA in April 2023 for amyotrophic ...

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS ...